e-Drug3D

2026

IBREXAFUNGERP

INN
IBREXAFUNGERP

cas 1207753-03-4

CLASS

ANTIINFECTIVES
A TRITERPENOID ANTIFUNGAL
TREATMENT OF VULVOVAGINAL CANDIDIASIS (VVC)
INHIBITS GLUCAN SYNTHASE

ROUTE (list)

ORAL

ATC code

J02AX07

PK parameters

Tmax 5 HOUR
VD 600 LITER
PPB 99 PERCENT
t1/2 20 HOUR

Target

TARGET GLUCAN SYNTHASE

DrugCentral

Beta-1,3-glucan synthase catalytic subunit 1 UNIPROT O13428 GSC1

1,3-Beta-D-glucan-UDP glucosyltransferase UNIPROT Q6FTN8 FKS1

Download SDF file

4H-1,4a-Propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid, 15-[(2R)-2-amino-2,3,3-trimethylbutoxy]-8-[(1R)-1,2-dimethylpropyl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-, (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-

Formula:
C44H67N5O4

Calculated chemical properties:

MW 729.02
NB_atoms 53
XLogP 7.28
PSA 100.391
NB_HD 2
NB_HA 9
fsp3 0.77
Lipinski(0=no;1=yes) 0

FDA
NDA 214900 (label) INN (IBREXAFUNGERP CITRATE) BREXAFEMME (SCYNEXIS) APPROVAL= AP YEAR= 2021 NEWMOLECULARENTITY